Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, Jackisch C, Antolin S, Solbach C, Aftimos P, Huober J, Untch M, Balic M, Reinisch M, Blohmer JU, Goncalves A, Rey J, Buechele T, Loibl S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S148-S149

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2022.03.074

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Ruprecht-Karls-Universität Heidelberg

Germany (DE) Rotkreuzklinikum München

Germany (DE) GBG Forschungs GmbH (German Breast Group)

Germany (DE) Beaumont Hospital

Ireland (IE) Technische Universität Dresden

Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM)

Germany (DE) Kliniken Essen-Mitte

Germany (DE) Philipps-Universität Marburg

Germany (DE) Sana Klinikum Offenbach

Germany (DE) Coruña University Hospital / Complexo Hospitalario Universitario A Coruña (CHUAC)

Spain (ES) Université libre de Bruxelles (ULB) / Free University of Brussels

Belgium (BE) Kantonsspital St.Gallen

Switzerland (CH) HELIOS Kliniken

Germany (DE) Charité - Universitätsmedizin Berlin

Germany (DE) Institute Paoli-Calmettes

France (FR)

How to cite

APA:

Marme, F., Hanusch, C., Furlanetto, J., Morris, P., Link, T., Denkert, C.,... Loibl, S. (2022). Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. In ANNALS OF ONCOLOGY (pp. S148-S149). AMSTERDAM: ELSEVIER.

MLA:

Marme, F., et al. "Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S148-S149.

BibTeX: Download